[go: up one dir, main page]

PE20061157A1 - Tiazolidinonas metasustituidas y su preparacion - Google Patents

Tiazolidinonas metasustituidas y su preparacion

Info

Publication number
PE20061157A1
PE20061157A1 PE2005001453A PE2005001453A PE20061157A1 PE 20061157 A1 PE20061157 A1 PE 20061157A1 PE 2005001453 A PE2005001453 A PE 2005001453A PE 2005001453 A PE2005001453 A PE 2005001453A PE 20061157 A1 PE20061157 A1 PE 20061157A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
alkenyl
ethyl
optionally substituted
Prior art date
Application number
PE2005001453A
Other languages
English (en)
Inventor
Volker Schulze
Knut Eis
Dirk Kosemund
Gerhard Siemeister
Uwe Eberspaecher
Imadul Islam
Dominic Brittain
Holger Hess-Stumpp
Olaf Prien
Lars Wortmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35895206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061157(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004061503A external-priority patent/DE102004061503A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20061157A1 publication Critical patent/PE20061157A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE T1, T2 Y T3 SON -CH= O -N= Y T2 ADICIONALMENTE ES (-CF)=; U ES -CR4= O -N= DONDE R4 ES H, CN, HALOGENO O METILO OPCIONALMENTE SUSTITUIDO CON HALOGENO; R1 ES ALQUILO C1-C3 O CICLOPROPILO OPCIONALMENTE SUSTITUIDO CON HALOGENO; R2 ES ALQUILO C1-C3, ALQUENILO C3-C4, ALQUINILO C3-C4, ENTRE OTROS; R3 ES K, L, M O R15; K ES ALQUILO C1-C3 O ALQUENILO C2-C4 OPCIONALMENTE SUSTITUIDO; L ES -O-(CH2)n-(CO)-NH-R8, -O-(CH2)n-(CO)-O-R8, ENTRE OTROS; R8 ES ALQUILO C1-C3, ALQUENILO C3-C4 O ALQUINILO(C3-C4) OPCIONALMENTE SUSTITUIDO CON CN, CICLOPROPILO O HALOGENO; M ES -NH-R9, -NH-(CO)-OH, ENTRE OTROS; R9 ES ALQUILO C1-C5, ALQUENILO C2-C4, HETEROCICLOALQUILO C2-C10, ENTRE OTROS; R15 ES HETEROCICLOALQUILO C2-C10 SUSTITUIDO OPCIONALMENTE CON UNO O MAS GRUPOS ALQUILO C1-C3 O -(CH2)n-ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (3-{[2-[1-CIANO-1-ETILCARBAMOIL-MET-(E O Z)-ILIDEN]-3-ETIL-4-OXO-TIAZOLIDIN-(5-(E/Z))-ILIDENMETIL]-AMINO}-FENIL)-AMIDA DEL ACIDO TETRAHIDRO-PIRAN-4-CARBOXILICO, 2-CIANO-N-ETIL-2-[3-ETIL-5-[1-{3-[3-(4-HIDROXIMETIL-PIPERIDIN-1-IL)-PROPIONILAMINO]-FENILAMINO}-MET-(E/Z)-ILIDEN]-4-OXO-TIAZOLIDIN-(2-(E O Z))-ILIDEN]-ACETAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LA POLO-QUINASA (Plk) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES TALES COMO EL CANCER, ENFERMEDADES CARDIOVASCULARES, ENFERMEDADES INFECCIOSAS, ENTRE OTRAS
PE2005001453A 2004-12-15 2005-12-14 Tiazolidinonas metasustituidas y su preparacion PE20061157A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004061503A DE102004061503A1 (de) 2004-12-15 2004-12-15 Metasubstituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US63777704P 2004-12-22 2004-12-22

Publications (1)

Publication Number Publication Date
PE20061157A1 true PE20061157A1 (es) 2006-11-16

Family

ID=35895206

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001453A PE20061157A1 (es) 2004-12-15 2005-12-14 Tiazolidinonas metasustituidas y su preparacion

Country Status (18)

Country Link
US (2) US20070015759A1 (es)
EP (1) EP1824834A1 (es)
JP (1) JP2008524139A (es)
KR (1) KR20070092740A (es)
AR (1) AR055698A1 (es)
AU (1) AU2005315835A1 (es)
BR (1) BRPI0519040A2 (es)
CA (1) CA2590396A1 (es)
CR (1) CR9183A (es)
GT (1) GT200500366A (es)
IL (1) IL183395A0 (es)
MX (1) MX2007007245A (es)
NO (1) NO20073631L (es)
PA (1) PA8656501A1 (es)
PE (1) PE20061157A1 (es)
TW (1) TW200628458A (es)
UY (1) UY29264A1 (es)
WO (1) WO2006063806A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
CA2641219A1 (en) * 2006-01-31 2007-08-09 Elan Pharmaceuticals, Inc. Alpha-synuclein kinase
US20110207796A1 (en) * 2008-02-13 2011-08-25 Elan Pharma International Limited Alpha-synuclein kinase
EP2141163A1 (de) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
JP5578705B2 (ja) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 （アリール）ジフルオロ酢酸エステル誘導体及びその製造方法
WO2014069434A1 (ja) * 2012-10-30 2014-05-08 カルナバイオサイエンス株式会社 新規チアゾリジノン誘導体
MX2015013348A (es) * 2013-03-20 2016-01-20 Bayer Pharma AG Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
CN105579457B (zh) * 2013-03-20 2017-08-04 拜耳制药股份公司 取代的n‑联苯‑3‑乙酰基氨基‑苯甲酰胺和n‑[3‑(乙酰基氨基)苯基]‑联苯‑甲酰胺及其作为wnt信号通路抑制剂用途
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
JP6704355B2 (ja) 2014-06-16 2020-06-03 ユニヴェルシテ・ドゥ・リール・２・ドロワ・エ・サンテ 化合物、医薬組成物、及び神経変性疾患の治療におけるそれらの使用
WO2023158514A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309758A (pt) * 2002-05-03 2005-02-15 Schering Ag Tiazolidinonas e seu uso como inibidortes de cinase semelhante a polo
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
IL183395A0 (en) 2007-09-20
TW200628458A (en) 2006-08-16
PA8656501A1 (es) 2006-09-08
CA2590396A1 (en) 2006-06-22
UY29264A1 (es) 2006-06-30
AR055698A1 (es) 2007-09-05
AU2005315835A1 (en) 2006-06-22
US20100048891A1 (en) 2010-02-25
CR9183A (es) 2008-01-21
JP2008524139A (ja) 2008-07-10
NO20073631L (no) 2007-09-12
BRPI0519040A2 (pt) 2009-01-13
KR20070092740A (ko) 2007-09-13
GT200500366A (es) 2006-12-04
EP1824834A1 (de) 2007-08-29
MX2007007245A (es) 2008-02-25
US20070015759A1 (en) 2007-01-18
WO2006063806A1 (de) 2006-06-22

Similar Documents

Publication Publication Date Title
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20141375A1 (es) Activadores de glucoquinasa
PE20121058A1 (es) Compuestos que modulan el receptor de androgenos
PE20091952A1 (es) Compuestos de tiazole y oxazole de sulfonamida de benzeno
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20090641A1 (es) Amidas heterociclicas
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20061157A1 (es) Tiazolidinonas metasustituidas y su preparacion
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20120780A1 (es) Nicotinamida sustituida como moduladores kcnq2/3
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
PE20091840A1 (es) Inhibidores de piridilo de la senalizacion hedgehog
PE20080077A1 (es) Derivados de sulfonilfenilo como antagonistas del receptor de il-8
PE20120790A1 (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
PE20090982A1 (es) Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20140610A1 (es) Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20060727A1 (es) Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)

Legal Events

Date Code Title Description
FC Refusal